Hande Tuncer MD in Milford, Massachusetts

Home Massachusetts Milford

Hande Tuncer MD has Hematology/oncology as her primary medical specialty. Their primary office is: 20 Prospect St in Milford, Massachusetts.

They're a part of the: Dana-farber Cancer Institute, Inc. medical group which has around 542 members. You can call their office at 508-473-1190 to schedule an appointment. They also accept the Medicare-approved amount as payment in full. They attended Sorry, her university is not listed and graduated in 1997 (around 27 years of experience). They are listed as doing telehealth appointments.

Hande H Tuncer MD Office Phone and Directions

Hande Tuncer MD
Dana-farber Cancer Institute, Inc.
20 Prospect St
Milford, Massachusetts 01757
508-473-1190

Patient Ratings
Please rate your experience with Hande Tuncer MD below to help others make a more informed decision. Thanks!

Current Rating: Loading...

Phone: 508-473-1190

Enter a starting address:

Healthcare Info for Hande Tuncer MD

Medical School: Sorry, her university is not listed
Graduation Year: 1997
The Primary Medical Specialty for Hande Tuncer MD is listed as: Hematology/oncology
Credentials: MD
Additional Credentials:
Approximate Years of Experience: 27
PAC (PECOS ID)#: 8628098951
NPI #: 1265446603
NPI Created On: 07/29/2006
NPI Last Updated Listed as: 06/22/2023
Primary Taxonomy Code: 207RH0003X
License Number:
226542
Listed Gender: Female

Insurance, Services, Charges

Forms of insurance accepted by include, but are not limited to:

Harvard Pilgrim Health Care Inc.
Medicare

They are listed as accepting new patients.

Services and Procedures include:

New patient office or other outpatient visit, typically 45 minutes
New patient office or other outpatient visit, typically 60 minutes
Established patient office or other outpatient visit, typically 15 minutes
Established patient office or other outpatient, visit typically 25 minutes
Established patient office or other outpatient, visit typically 25 minutes
Established patient office or other outpatient, visit typically 40 minutes
Established patient office or other outpatient, visit typically 40 minutes

They took part in Medicare's Electronic Health Record Incentive Program which was designed to help move people over to electronic records and improve the systems that were already in place.
They took part in the Medicare Physician Quality Reporting System (PQRS).

Open Payments Data. This can include items to test (Durable Medical Equipment (DME)), Biological, Drug Samples, etc. This data must be reported to CMS.

Payments Total: $1,768

Number of Payments:: 1

Form of Payment: Cash or cash equivalent

Third party is a Charity:: No

Record ID:: 788048623

Being Disputed:: No

Product Related: Yes

Drug or Biological: Drug

Product Category #1: Oncology

Name of Drug #1: DARZALEX

Open Associated Drug #1: 57894-502-05

Payments Total: $677

Number of Payments:: 1

Form of Payment: Cash or cash equivalent

Record ID:: 796180057

Being Disputed:: No

Product Related: Yes

Payments Total: $1,950

Number of Payments:: 1

Form of Payment: Cash or cash equivalent

Record ID:: 783535673

Being Disputed:: No

Product Related: No

Payments Total: $3,053

Number of Payments:: 1

Form of Payment: Cash or cash equivalent

Third party is a Charity:: No

Record ID:: 829572347

Being Disputed:: No

Product Related: Yes

Drug or Biological: Drug

Product Category #1: Oncology

Name of Drug #1: CALQUENCE

Open Associated Drug #1: 0310-0512-28

Payments Total: $3,053

Number of Payments:: 1

Form of Payment: Cash or cash equivalent

Third party is a Charity:: No

Record ID:: 829728871

Being Disputed:: No

Product Related: Yes

Drug or Biological: Drug

Product Category #1: Oncology

Name of Drug #1: CALQUENCE

Open Associated Drug #1: 0310-0512-28

Payments Total: $1,943

Number of Payments:: 1

Form of Payment: Cash or cash equivalent

Third party is a Charity:: No

Record ID:: 829878369

Being Disputed:: No

Product Related: Yes

Drug or Biological: Drug

Product Category #1: Oncology

Name of Drug #1: CALQUENCE

Open Associated Drug #1: 0310-0512-28